Arvinas
Pharmaceutical company focused on protein degradation approaches to develop novel drugs to treat cancer and other diseases.
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (49 %) | 114 % | 181 % | (40 %) | 236 % | 9 % | (46 %) |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (573 %) | (418 %) | (200 %) | (503 %) | (92 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (547 %) | (409 %) | (215 %) | (468 %) | (76 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 497 % | 386 % | 240 % | 484 % | 132 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Arvinas, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies to treat debilitating and life-threatening diseases. The company operates in the biotechnology sector and primarily serves patients suffering from conditions caused by disease-causing proteins. Arvinas leverages its proprietary technology platform to create proteolysis targeting chimeras (PROTAC® protein degraders), which are designed to harness the body's natural protein disposal system to selectively degrade harmful proteins.
The company's business model revolves around the discovery, development, and commercialization of these novel therapies. Arvinas generates revenue through partnerships, collaborations, and licensing agreements with other pharmaceutical companies, as well as through the potential commercialization of its own drug candidates.
Arvinas operates in the global biopharmaceutical market, targeting a range of diseases including cancer and neurodegenerative disorders. The company aims to improve patient outcomes by providing targeted, effective treatments that address the underlying causes of these diseases.
Keywords: protein degradation, PROTAC, biopharmaceutical, clinical-stage, biotechnology, disease-causing proteins, innovative therapies, cancer, neurodegenerative disorders, proprietary technology.
